WBB Securities analyst Stephen Brozak came out today with a favorable report on Caladrius Biosciences Inc (NASDAQ:CLBS), after the company announced Tuesday that it has signed a collaboration agreement with Sanford Research to develop the company’s T regulatory cell therapy candidate, CLBS03 for treating recent-onset type 1 diabetes in adolescents.
Brozak noted, “The collaboration between Sanford and CLBS may result in a groundbreaking immunotherapy and a vastly improved quality of life for T1D adolescent patients. The announcement follows encouraging Phase I data in which some patients had long-term stabilized insulin production. If effective, CLBS03 may be able to lower the dependence of T1D patients on constant insulin injections because it protects insulin-producing beta cells from further destruction and possibly promotes restoration. It also may lower dependence on immunosuppressive drugs, which leave T1D patients vulnerable to infection.”
Bottom line: “Given the recent announcement of the Sanford Research Treg collaboration an underlying assessment for the collaboration reinforces not only the technology potential, but also the strength of the partnering potential.”
Brozak reiterated a Strong Buy rating on Caladrius Biosciences shares, with a price target of $7, which represents a potential upside of 300% from where the stock is currently trading.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Stephen Brozak has a total average return of 43.7% and a 57.1% success rate. Brozak has a -16.2% average return when recommending CLBS, and is ranked #267 out of 3766 analysts.
All the 4 analysts polled by TipRanks rate Caladrius Biosciences stock a Buy. With a return potential of 500%, the stock’s consensus target price stands at $10.50.